AU2023214599A1 - Theragnostic folate conjugates - Google Patents

Theragnostic folate conjugates Download PDF

Info

Publication number
AU2023214599A1
AU2023214599A1 AU2023214599A AU2023214599A AU2023214599A1 AU 2023214599 A1 AU2023214599 A1 AU 2023214599A1 AU 2023214599 A AU2023214599 A AU 2023214599A AU 2023214599 A AU2023214599 A AU 2023214599A AU 2023214599 A1 AU2023214599 A1 AU 2023214599A1
Authority
AU
Australia
Prior art keywords
compound according
radiometal
compound
dota
folate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023214599A
Other languages
English (en)
Inventor
Anna Elisabeth BECKER
Martina Benesova
Sara Dorina BUSSLINGER
Luisa Maria DEBERLE
Viola Groehn
Patrycja Guzik
Rudolf Moser
Cristina Magdalena Mueller
Marie-Luise RENZ
Roger Schibli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2023214599A1 publication Critical patent/AU2023214599A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2023214599A 2022-02-01 2023-01-30 Theragnostic folate conjugates Pending AU2023214599A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22154653.4 2022-02-01
EP22154653 2022-02-01
PCT/EP2023/052116 WO2023148115A1 (en) 2022-02-01 2023-01-30 Theragnostic folate conjugates

Publications (1)

Publication Number Publication Date
AU2023214599A1 true AU2023214599A1 (en) 2024-09-19

Family

ID=80119142

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023214599A Pending AU2023214599A1 (en) 2022-02-01 2023-01-30 Theragnostic folate conjugates

Country Status (9)

Country Link
US (1) US20250108138A1 (cg-RX-API-DMAC7.html)
EP (1) EP4472676A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025504028A (cg-RX-API-DMAC7.html)
KR (1) KR20240142514A (cg-RX-API-DMAC7.html)
CN (1) CN118660723A (cg-RX-API-DMAC7.html)
AU (1) AU2023214599A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243526A1 (cg-RX-API-DMAC7.html)
IL (1) IL314507A (cg-RX-API-DMAC7.html)
WO (1) WO2023148115A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025220711A1 (ja) * 2024-04-17 2025-10-23 日本メジフィジックス株式会社 化合物、放射性標識化合物及びその製造方法、並びに放射性医薬組成物
WO2026014283A1 (ja) * 2024-07-09 2026-01-15 日本メジフィジックス株式会社 化合物、放射性標識化合物およびその製造方法、並びに放射性医薬組成物

Also Published As

Publication number Publication date
CN118660723A (zh) 2024-09-17
CA3243526A1 (en) 2023-08-10
EP4472676A1 (en) 2024-12-11
US20250108138A1 (en) 2025-04-03
IL314507A (en) 2024-09-01
JP2025504028A (ja) 2025-02-06
WO2023148115A1 (en) 2023-08-10
KR20240142514A (ko) 2024-09-30

Similar Documents

Publication Publication Date Title
ES2990974T3 (es) Conjugados de folato de entidades fijadoras de albúmina
CN109053616B (zh) 前列腺特异性膜抗原(psma)的标记的抑制剂及其用途
JP5308829B2 (ja) 癌の画像化および処置
CN113573742A (zh) 新型肿瘤抗原结合剂及其用途
US20250108138A1 (en) Theragnostic folate conjugates
CN116082306A (zh) 一种靶向fap及psma双靶点抑制剂、分子探针及应用
EP2948186A1 (en) Tetrazines/trans-cyclooctenes in solid phase synthesis of labeled peptides
WO2019101729A1 (en) A double-labeled probe for molecular imaging and use thereof
WO2019092242A1 (en) A double-labeled probe for molecular imaging and use thereof
US20250127938A1 (en) Theragnostic folate conjugates
US20110250133A1 (en) Gastrin releasing peptide compounds
US20250339568A1 (en) Precursor and radiotracer for neuroendocrine theranostics
HK40110380A (en) Theragnostic folate conjugates
HK40109744A (en) Theragnostic folate conjugates
US20240115744A1 (en) Fibrin-binding compounds for imaging and treatment
EP4282439A1 (en) Radioisotope labeled sstr2-agonists with linkers
KR20250011145A (ko) 개선된 신장 청소율을 갖는 전립선-특이적 막 항원(psma) 리간드
HK40054611A (en) Novel tumor antigen binding agents and uses thereof